AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23589670 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 45
Study 23589670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21342243 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring-based disease management strategy
Number of subjects: 62
Study 21342243 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 62
Study 19136753 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (1, 1.5 and 2 mg based on body weight)
Number of subjects: 70
Study 19136753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 70
Study 17197959 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography followed by endoscopic papillotomy for bile duct stones (EEI)
Number of subjects: 103
Study 17197959 — intervention group
Group type: COMPARATOR
Intervention: Early conservative management (ECM)
Number of subjects: 103
Study 15008829 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand Diabetes Passport
Number of subjects: 398
Study 15008829 — intervention group
Group type: COMPARATOR
Intervention: Control booklet
Number of subjects: 398
Study 11464977 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg MSL-109
Number of subjects: 179
Study 11464977 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg MSL-109
Number of subjects: 179
Study 11464977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 11464977 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109 (60 mg and 15 mg combined) in D+/R- subgroup
Number of subjects: 179
Study 11464977 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109 (60 mg and 15 mg combined) in D+/R+ and D-/R+ subgroup
Number of subjects: 179
Study 11464977 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109
Number of subjects: 179
Study 9766703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for anterior MI (20 patients)
Number of subjects: 70
Study 9766703 — intervention group
Group type: COMPARATOR
Intervention: No exercise training for anterior MI (20 patients)
Number of subjects: 70
Study 9766703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for inferior MI (15 patients)
Number of subjects: 70
Study 9766703 — intervention group
Group type: COMPARATOR
Intervention: No exercise training for inferior MI (15 patients)
Number of subjects: 70
Study 8116724 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Doppler velocimetry
Number of subjects: 1598
Study 8116724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Doppler velocimetry)
Number of subjects: 1598
Study 3661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (75‐100 mg/m2) and concomitant radiotherapy (20.00 Gy in 1 week) followed by full course (120 mg/m2 of cisplatin and 38.40 Gy of radiation)
Number of subjects: 50
Study 3661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Full course (FC) therapy
Number of subjects: 50
Study 3661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial course (PC) therapy
Number of subjects: 50
Study 3661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 50
Study 31317668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab liquid formulation (100 mg) administered subcutaneously via prefilled syringe or autoinjector
Number of subjects: 244
Study 31317668 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized formulation of Mepolizumab
Number of subjects: 244
Study 31317668 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment adverse events
Number of subjects: 244
Study 28103433 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 68
Study 27270245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (LE)
Number of subjects: 14
Study 27270245 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil lipid emulsion (LE)
Number of subjects: 14
Study 25513749 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (executive function training)
Number of subjects: 55
Study 25513749 — intervention group
Group type: COMPARATOR
Intervention: Control group (easier, consistent-difficulty planning tasks)
Number of subjects: 55
Study 23931876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 81
Study 23931876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 17269591 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary treatment of gynecomastia
Number of subjects: 0
Study 12511716 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (SM)
Number of subjects: 214
Study 12511716 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 214
Study 10357727 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg orlistat 3 times daily
Number of subjects: 729
Study 10357727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 7589634 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and GH (4 IU)
Number of subjects: 64
Study 7589634 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and GH (12 IU)
Number of subjects: 64
Study 7589634 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and GH (24 IU)
Number of subjects: 64
Study 7589634 — intervention group
Group type: COMPARATOR
Intervention: hMG and placebo
Number of subjects: 64
Study 7589634 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG and GH (any dose)
Number of subjects: 64
Study 1936001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 30
Study 1936001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7065664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide ointment
Number of subjects: 15
Study 7065664 — intervention group
Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 15
Study 30830077 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) monotherapy
Number of subjects: 50
Study 30830077 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) added to timolol (0.5%)
Number of subjects: 50
Study 30830077 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) added to dorzolamide (2%)
Number of subjects: 50
Study 30830077 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening use of Travoprost
Number of subjects: 50
Study 28856602 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible (OD) ticagrelor tablets (90 mg)
Number of subjects: 78
Study 28856602 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) ticagrelor tablets
Number of subjects: 78
Study 25247485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) with low-dose dexamethasone maintenance (HD-DXM-M group)
Number of subjects: 61
Study 25247485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) without low-dose dexamethasone maintenance (HD-DXM-nM group)
Number of subjects: 61
Study 25247485 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (control group)
Number of subjects: 61
Study 25247485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone with low-dose dexamethasone maintenance (HD-DXM-M group)
Number of subjects: 61
Study 23460266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 0
Study 23460266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21269443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 0
Study 21269443 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched according to mean age, sex, and general intelligence)
Number of subjects: 0
Study 19227171 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg x day(‐1) + morphine 3.3 mg x day(‐1) (group MB)
Number of subjects: 100
Study 19227171 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 3.3 mg x day(‐1) alone (group M)
Number of subjects: 100
Study 19227171 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg x day(‐1) alone (group B)
Number of subjects: 100
Study 16338599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1g/day)
Number of subjects: 92
Study 16338599 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (450 mg/day)
Number of subjects: 92
Study 16338599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 15085555 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + fat-free yoghurt
Number of subjects: 4
Study 15085555 — intervention group
Group type: COMPARATOR
Intervention: Glucose + full-fat yoghurt
Number of subjects: 4
Study 15085555 — intervention group
Group type: COMPARATOR
Intervention: Aspartame + full-fat yoghurt
Number of subjects: 4
Study 15085555 — intervention group
Group type: COMPARATOR
Intervention: Aspartame + fat-free yoghurt
Number of subjects: 4
Study 11244702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg.kg‐1) with non-invasive blood pressure measurement in the ipsilateral arm
Number of subjects: 31
Study 9286852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily for 3 weeks
Number of subjects: 0
Study 9286852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily
Number of subjects: 0
Study 9286852 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day
Number of subjects: 0
Study 9286852 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem SR 120 mg twice daily
Number of subjects: 0
Study 8357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (B)
Number of subjects: 224
Study 8357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (C)
Number of subjects: 224
Study 8357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen and graduated compression stockings (D)
Number of subjects: 224
Study 8357095 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 224
Study 3553586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75, 100, or 125 mg/day)
Number of subjects: 0
Study 3553586 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75, 100, or 125 mg/day)
Number of subjects: 0
Study 3553586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 29504788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce weight loss
Number of subjects: 4774
Study 29504788 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education and support control group
Number of subjects: 4774
Study 27901219 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage + Reiki (G2)
Number of subjects: 122
Study 27901219 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage + Rest (G1)
Number of subjects: 122
Study 27901219 — intervention group
Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 122
Study 24945556 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief chair-side counselling by a dentist based on the 5 A's approach
Number of subjects: 70
Study 24945556 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 70
Study 22615841 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored guided self‐help treatment targeting depression and comorbid symptoms
Number of subjects: 121
Study 22615841 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized (non‐tailored) Internet‐based treatment for depression
Number of subjects: 121
Study 22615841 — intervention group
Group type: COMPARATOR
Intervention: Active control group (monitored online discussion group)
Number of subjects: 121
Study 20801727 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-activation manipulation
Number of subjects: 79
Study 20801727 — intervention group
Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 79
Study 17715212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg)
Number of subjects: 10
Study 17715212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (8 mg)
Number of subjects: 10
Study 17715212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (12 mg)
Number of subjects: 10
Study 17715212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (16 mg)
Number of subjects: 10
Study 17715212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17240931 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated size 40 K3 rotary file with gutta-percha and AH-26 sealer
Number of subjects: 26
Study 17240931 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturated without a separated file (Group 2)
Number of subjects: 26
Study 17240931 — intervention group
Group type: COMPARATOR
Intervention: Negative control (obturated and sealed with nail varnish)
Number of subjects: 26
Study 17240931 — intervention group
Group type: COMPARATOR
Intervention: Positive control (obturated without sealer)
Number of subjects: 26
Study 12472786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate in sucrose (SFGC)
Number of subjects: 2338
Study 12472786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2338
Study 11052633 — intervention group
Group type: EXPERIMENTAL
Intervention: AVSS through commercially available virtual glasses (VG-AVSS)
Number of subjects: 37
Study 11052633 — intervention group
Group type: COMPARATOR
Intervention: No AVSS
Number of subjects: 37
Study 8851614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fleroxacin; single-dose trial; specific dosage not mentioned.
Number of subjects: 0
Study 1519232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (5.000 anti XaU once daily)
Number of subjects: 39
Study 1519232 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (5.000 IU three times daily)
Number of subjects: 39
Study 6666231 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN treatment (240 mg daily, 6 X 40 mg)
Number of subjects: 10
Study 6666231 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN treatment
Number of subjects: 10
Study 6666231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot Strike (FFS)
Number of subjects: 18
Study 31860830 — intervention group
Group type: COMPARATOR
Intervention: Rear-foot Strike (RFS)
Number of subjects: 18
Study 31860830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FFS and RFS
Number of subjects: 18
Study 31860830 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH
Number of subjects: 18
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 63
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 63
Study 28632486 — intervention group
Group type: COMPARATOR
Intervention: Switching taxane
Number of subjects: 63
Study 28632486 — intervention group
Group type: COMPARATOR
Intervention: Not switching taxane
Number of subjects: 63
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-induced decrease in %ARNL
Number of subjects: 63
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 63
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 63
Study 28632486 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 63
Study 26555148 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES treatment group (8-week daily NMES treatment)
Number of subjects: 32
Study 26555148 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual or conventional treatments)
Number of subjects: 32
Study 24789375 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching (minimum of 6 h/d)
Number of subjects: 419
Study 24789375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate eyedrops, 1% (1 drop daily)
Number of subjects: 419
Study 24789375 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Patching and Atropine)
Number of subjects: 419
Study 22078979 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide (150 mg/12.5 mg day)
Number of subjects: 65
Study 22078979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/hydrochlorothiazide (5 mg/12.5 mg day)
Number of subjects: 65
Study 19284181 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal-Q10 (new formulation)
Number of subjects: 20
Study 19284181 — intervention group
Group type: COMPARATOR
Intervention: Solubilizate 1
Number of subjects: 20
Study 19284181 — intervention group
Group type: COMPARATOR
Intervention: Oil-based formulation
Number of subjects: 20
Study 19284181 — intervention group
Group type: COMPARATOR
Intervention: Solubilizate 2
Number of subjects: 20
Study 17888059 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure massage therapy
Number of subjects: 80
Study 17888059 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 80
Study 15135263 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 40
Study 11922742 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 dissection with gastrectomy
Number of subjects: 1403
Study 11922742 — intervention group
Group type: COMPARATOR
Intervention: D1 dissection with gastrectomy
Number of subjects: 1403
Study 11922742 — intervention group
Group type: COMPARATOR
Intervention: N1 group
Number of subjects: 1403
Study 11922742 — intervention group
Group type: COMPARATOR
Intervention: N2 group
Number of subjects: 1403
Study 11922742 — intervention group
Group type: COMPARATOR
Intervention: N3 group
Number of subjects: 1403
Study 10808843 — intervention group
Group type: EXPERIMENTAL
Intervention: Armchair with integral pressure-reducing cushion
Number of subjects: 0
Study 10808843 — intervention group
Group type: COMPARATOR
Intervention: Existing bedside armchair (Control)
Number of subjects: 0
Study 7602620 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical care supplemented with a psychosocial intervention program
Number of subjects: 820
Study 7602620 — intervention group
Group type: COMPARATOR
Intervention: Surgical care
Number of subjects: 820
Study 2294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (5 micrograms)
Number of subjects: 129
Study 2294263 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (18 mg)
Number of subjects: 129
Study 2294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective preference
Number of subjects: 129
Study 13094 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg iv chlorpheniramine
Number of subjects: 10
Study 13094 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5 mg/kg iv aminophylline
Number of subjects: 10
Study 13094 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg po chlorpheniramine
Number of subjects: 10
Study 13094 — intervention group
Group type: COMPARATOR
Intervention: 30 mg po butabarbital
Number of subjects: 10
Study 13094 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 10
Study 29064626 — intervention group
Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP 1 to 3 mg/L
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LDL-C and low hsCRP
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LDL-C and high hsCRP
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDL-C and low hsCRP
Number of subjects: 5380
Study 29064626 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDL-C and high hsCRP
Number of subjects: 5380
Study 27591455 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (Ropivacaine 0.15% plus Sufentanil 0.2μg/mL solution at 5mL/h)
Number of subjects: 130
Study 27591455 — intervention group
Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Ropivacaine 0.1% plus Sufentanil 0.2μg/mL at 10mL/h)
Number of subjects: 130
Study 27591455 — intervention group
Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Same solution as group A)
Number of subjects: 130
Study 27591455 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (Group A)
Number of subjects: 130
Study 27591455 — intervention group
Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Group B and C)
Number of subjects: 130
Study 24852915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 210
Study 24852915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24852915 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA ≥47 μV
Number of subjects: 210
Study 22408272 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal mixture of bupivacaine and morphine followed by oral oxycodone
Number of subjects: 50
Study 22408272 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 50
Study 19597422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (0.24 mg/kg) and G-CSF (10 microg/kg for 4 days)
Number of subjects: 35
Study 19597422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor and G-CSF
Number of subjects: 35
Study 19597422 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 35
Study 18456059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee arthroplasty
Number of subjects: 104
Study 18456059 — intervention group
Group type: COMPARATOR
Intervention: Mobile-bearing total knee arthroplasty
Number of subjects: 104
Study 18456059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 16162699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone propionate, 1,000 microg/d) for 4 weeks
Number of subjects: 86
Study 11409425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (t-PA) in patients with Apo E2 phenotype (27 patients)
Number of subjects: 409